Roche takes immense pride in being a foundational partner in the landmark PrOSPeCT initiative and public-private partnership. The collaboration with Omico and other esteemed foundational partners underscores Roche’s firm belief that partnerships are crucial for achieving speed, scalability, and efficiency in bringing the benefits of personalised healthcare to patients.

With a commitment of $20 million, Roche Australia’s investment in the initiative reaffirms its dedication to accelerating the development and implementation of innovative healthcare solutions. PrOSPeCT represents a significant stride forward in precision oncology, paving the way for personalised pathways for patients in their battle against cancer.

Stuart Knight, General Manager of Roche Products expressed his excitement about the launch, stating, “At Roche, our mission is to improve patient outcomes and transform the way healthcare is delivered. Our partnership in PrOSPeCT signifies a remarkable milestone in our pursuit of this mission. By harnessing the power of precision oncology and facilitating greater accessibility to clinical trials, this program aims to make a real difference in the lives of Australians affected by cancer”.

Allison Rossiter, Managing Director of Roche Diagnostics, emphasised the importance of collaboration in driving innovation and advancements in cancer diagnosis. “We are thrilled to be part of PrOSPeCT, bringing together our expertise in diagnostics technologies and precision medicine. This collaborative effort will enable patients to access the power of cutting-edge diagnostic technologies and in-turn aims to facilitate greater accessibility to potential therapies”.

Roche is committed to integrating innovation into existing healthcare pathways, enabling personalised care, and fostering partnerships across the healthcare ecosystem. Through collaborations like PrOSPeCT and enabling clinical trials, we can unlock the value of personalised healthcare for patients in Australia and around the world.

As one of the world's leading innovative pharmaceutical and diagnostic companies in oncology healthcare, Roche is uniquely positioned to realise the transformative potential of oncology personalised healthcare (PHC) – a strategy that aims to find the right treatment for each patient at the right time, based on the molecular biology of their specific tumours.

Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics.

The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.

In recognising our endeavor to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the thirteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work.

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

For more information, please visit www.roche-australia.com.